Researchers Linked Pyrimidine Synthesis to Cystic Fibrosis
A new study identified a metabolic pathway that drives lung remodeling in cystic fibrosis patients.
Updated on Sept. 22, 2026 in Asthma
Live Poll
Do you trust that new research into metabolic pathways will improve chronic disease treatment outcomes?
Scientists have determined that the de novo pathway of pyrimidine synthesis acts as a key driver of lung remodeling in cystic fibrosis. The research reveals how epithelial cells with CFTR mutations undergo metabolic changes that affect patient health.
Why it matters
Understanding this compensatory metabolic mechanism provides new insight into why cystic fibrosis lungs undergo pathological changes. This discovery highlights a specific pathway that also enables the pathogen Pseudomonas aeruginosa to persist.
CFTR-mutant epithelial cells show impaired mitochondrial bioenergetics, which prompts a compensatory increase in pyrimidine synthesis activity. This process effectively links mitochondrial oxidative metabolism to cell proliferation.
The players
Pseudomonas aeruginosa
This is a common bacterium that serves as the predominant pathogen affecting the lungs of individuals with cystic fibrosis.
The details
The study found that CFTR-mutant epithelial cells activate de novo pyrimidine synthesis to compensate for impaired mitochondrial bioenergetics, leading to cell proliferation and lung tissue remodeling. Simultaneously, the pathogen Pseudomonas aeruginosa exhibits convergent adaptation, utilizing its own pyrimidine synthesis machinery to amplify its biomass and maintain persistence within the lung environment.
Timeline
The research findings were published on September 22, 2026.
The Big Picture
This discovery shifts the understanding of cystic fibrosis from a strictly genetic disorder to one influenced by complex metabolic feedback loops. By identifying this de novo pathway, the research bridges the gap between mitochondrial dysfunction and the proliferation of both host cells and pathogens.
This research provides a new potential target for future therapies aimed at slowing lung remodeling in cystic fibrosis patients. While currently experimental, it offers a refined understanding of the cellular changes that contribute to long-term lung damage.
The takeaway
This study underscores the role of metabolic adaptation in chronic respiratory disease. Future research will likely focus on whether blocking this specific pyrimidine synthesis pathway can effectively limit both lung cell remodeling and bacterial colonization.
Further reading
For more information on respiratory disease, explore our Asthma section.
More information
Read the full peer-reviewed research article for comprehensive details on the study.
Source note: This article includes information reported by Nature.
Live Poll
Do you trust that new research into metabolic pathways will improve chronic disease treatment outcomes?
